Ares Life Sciences to Acquire Antigen Laboratories, Inc., in the United States
News Apr 15, 2013
Ares recently signed an agreement to acquire Greer Laboratories, Inc. a leader in U.S. allergy immunotherapy (AIT) market. The acquisition of Antigen Laboratories is a continuation of Ares' strategic focus on the U.S. AIT market. It is also the majority shareholder of the French based Stallergenes S.A., a pioneer and leader in immunotherapy treatments by sublingual administration. Ares believes there is significant growth potential in the AIT business globally, particularly in the US which currently only represents 10% of the European market and is expected to grow significantly over the next few years.
Jacques Theurillat, CEO of Ares Life Sciences, commented: "As an FDA licensed manufacturer, Antigen has one of the most comprehensive offerings of allergenic extracts in the United States and has a long track record of serving the needs for the ENT specialists. We view the acquisition of Antigen as very complementary to our other investments in the allergy market."
Theron E. Odlaug, Planet Biopharmaceuticals Executive Chairman and CEO, commented, "We are looking forward to becoming a member of the Ares portfolio of life science companies and the resources they will provide to help us continue to grow."
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE
What Does the Future of Vaccines and Immunotherapy Look Like?News
Innovative biomaterials could enhance vaccines against HIV and other infectious diseases and immunotherapies for patients with cancer or dampen responses in autoimmune disorders, allergies and transplanted organ recipients. A review of these efforts was recently released.READ MORE
CMC Biologics Announces Development and Manufacturing Agreement with Harpoon TherapeuticsNews
Companies have entered into agreement for the development and manufacturing of three TriTAC molecules for the treatment of cancers.READ MORE